Anthos Therapeutics Inc.

PwC: Regulatory, Policy Uncertainty Constrain Dealmaking Life sciences deal volume and total valuation has been sluggish approaching the midpoint of 2025, even compared to the below-average numbers p

Woodcock: Don’t Do The Wrong Study, Even If FDA Tells You To Janet Woodcock said she has told drug developers not to blindly follow agency advice, an unusual comment from a former US Food and Drug Adm

Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso

Merger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu